Q-omics provides the consensus-scored C6orf15 profile across patient tissues and cancer cell-line models. C6orf15 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, C6orf15 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, C6orf15 RNA expression shows 9,351 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BLCA, COAD, and TGCT as cancer lineages where C6orf15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C6orf15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C6orf15 survival associations across molecular data types. C6orf15 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C6orf15 RNA expression–survival associations across cancer types. High C6orf15 expression shows unfavorable associations in BLCA, COAD, LGG, SKCM and MESO, but favorable associations in ACC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for C6orf15 RNA expression.
This table summarizes C6orf15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for C6orf15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C6orf15 shows lower tumor expression in BRCA and higher tumor expression in COAD, THCA, LUSC, UCEC and LUAD. The COAD box plot shows higher C6orf15 RNA expression in tumor versus normal tissue (log2 FC = +1.805, t-test p < 0.001).
This table shows molecular features associated with C6orf15 in patient tissues and cancer cell lines. In patient samples, C6orf15 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, C6orf15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
